[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 28 of about 28
1. Hara I, Hikosaka S, Eto H, Miyake H, Yamada Y, Soejima T, Sugimura K, Kamidono S: Successful treatment for squamous cell carcinoma of the female urethra with combined radio- and chemotherapy. Int J Urol; 2004 Aug;11(8):678-82
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment for squamous cell carcinoma of the female urethra with combined radio- and chemotherapy.
  • We report on two cases of women with locally advanced squamous cell carcinoma of the urethra.
  • Treatment comprised combined radiotherapy to 60 Gy and chemotherapy with 5-fluorouracil and cisplatin.
  • Patient 1 experienced recurrent inguinal lymph node metastasis on the contralateral side at 42 months after initial treatment, and the same treatment was performed followed by surgical excision.
  • Both patients remain alive with no evidence of disease, at 12 months after recurrence in Patient 1, and at 27 months after treatment in Patient 2.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Urethral Neoplasms / drug therapy. Urethral Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Antineoplastic Agents / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Therapy, Combination. Female. Fluorouracil / administration & dosage. Humans. Middle Aged

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15285764.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Number-of-references] 9
  •  go-up   go-down


2. Tanaka H, Masuda H, Komai Y, Yokoyama M, Iwai A, Numao N, Sakai Y, Saito K, Fujii Y, Kobayashi T, Kawakami S, Kihara K: [Primary adenocarcinoma of the female urethra treated by multimodal therapy]. Hinyokika Kiyo; 2009 Jan;55(1):43-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary adenocarcinoma of the female urethra treated by multimodal therapy].
  • Magnetic resonance imaging showed a tumor surrounding the urethra, which invaded to the vesical triangle and the anterior vaginal wall.
  • Serum levels of carcinoembryonic antigen and carbohydrate antigen 19-9 were elevated, but squamous cell carcinoma antigen and prostate specific antigen were within normal limits.
  • First, the patient received local chemoradiotherapy and systemic chemotherapy using a fluoropyrimidine drug TS-1 and cisplatin.
  • The tumor markers declined to within normal limits after this preoperative therapy.
  • The final diagnosis was urethral adenocarcinoma, pT4N0, Stage IV.
  • [MeSH-major] Adenocarcinoma, Mucinous / therapy. Urethral Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Invasiveness. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / therapy. Vaginal Neoplasms / pathology. Vaginal Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19227213.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


3. Gillitzer R, Hampel C, Wiesner C, Hadaschik B, Thüroff J: Single-institution experience with primary tumours of the male urethra. BJU Int; 2008 Apr;101(8):964-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single-institution experience with primary tumours of the male urethra.
  • OBJECTIVE: To assess primary tumours of the urethra in males.
  • PATIENTS AND METHODS: We retrospectively reviewed our database from 1986 to 2006 for primary tumours of the male urethra; nine patients with primary tumours of the urethra were analysed and follow-up information was obtained.
  • RESULTS: Three patients had tumours of the prostatic urethra, two of which had proliferating focal inflammation and one a low-grade, superficial urothelial cancer.
  • Six patients had carcinoma of the bulbar or penile urethra, including two with previous local percutaneous radiotherapy for prostate cancer.
  • One patient had adjuvant chemotherapy after surgery.
  • CONCLUSION: Primary carcinoma of the male urethra is a rare entity.
  • Multimodal therapy might be required to obtain an optimum oncological outcome.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Carcinoma, Transitional Cell / pathology. Urethral Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy. Epidemiologic Methods. Humans. Lymphatic Metastasis. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18070169.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


Advertisement
4. Trabulsi EJ, Hoffman-Censits J: Chemotherapy for penile and urethral carcinoma. Urol Clin North Am; 2010 Aug;37(3):467-74
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy for penile and urethral carcinoma.
  • Although surgery is the mainstay of curative treatment of carcinomas of the penis and urethra, there is a role for systemic cytotoxic chemotherapy for locally advanced, unresectable, or metastatic tumors.
  • Although this field is limited by a paucity of clinical trials or prospective data, the available single institutional retrospective reviews indicate that multi-agent cisplatin-based combination chemotherapy regimens have significant activity and may allow curative surgery for patients with otherwise unresectable tumors.
  • This article reviews the available literature on chemotherapy for carcinoma of the penis and urethra in the neoadjuvant, adjuvant, and metastatic setting.
  • [MeSH-major] Penile Neoplasms / drug therapy. Urethral Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Chemotherapy, Adjuvant. Humans. Male. Neoadjuvant Therapy. Taxoids / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20674701.001).
  • [ISSN] 1558-318X
  • [Journal-full-title] The Urologic clinics of North America
  • [ISO-abbreviation] Urol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids
  • [Number-of-references] 34
  •  go-up   go-down


5. Hong JY, Choi MK, Uhm JE, Park MJ, Lee J, Park SH, Park JO, Kim WS, Kang WK, Lee HM, Choi HY, Lim H: Palliative chemotherapy for non-transitional cell carcinomas of the urothelial tract. Med Oncol; 2009;26(2):186-92
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palliative chemotherapy for non-transitional cell carcinomas of the urothelial tract.
  • Non-transitional cell carcinomas of the urothelial tract comprise 5-10% of urothelial cancers.
  • Clinical information regarding the clinical behavior and chemotherapy outcome of non-transitional cell carcinomas of the urothelial tract are incomplete due to their rarity.
  • The object of this study was to evaluate the clinical features and the efficacy of palliative chemotherapy in advanced non-transitional cell carcinomas of the urothelial tract.
  • We analyzed the clinical records of 21 consecutive patients who received palliative chemotherapy for unresectable or metastatic non-transitional cell carcinomas of the urothelial tract between January 1995 and November 2007.
  • All the 21 patients received first-line chemotherapy with platinum-based regimens which are known to be effective in transitional cell urothelial carcinomas.
  • The primary sites of involvement were the bladder, urethra, urachus, and ureter in 43%, 29%, 19%, and 10% of the patients, respectively.
  • Adenocarcinoma was the most common histological type (67%); squamous cell carcinoma and small cell carcinoma comprised 24 and 10% of the histologic types, respectively.
  • With a median duration of follow-up of 32 months (range, 12-71 months), the median overall survival for all 21 patients from the day of first-line chemotherapy was 13 months (95% CI, 6.8-19.2).
  • The median overall survival of patients who received platinum-based palliative chemotherapy for advanced non-transitional cell carcinomas was comparable to previous studies for patients with transitional cell carcinomas.
  • Adenocarcinomas appear to have a favorable prognosis for the survival of the patients who received platinum-based chemotherapy for advanced non-transitional cell carcinomas.
  • [MeSH-major] Carcinoma / drug therapy. Palliative Care. Urologic Neoplasms / drug therapy. Urothelium
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adult. Aged. Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Female. Humans. Male. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 2007 Feb;69(2):255-9 [17320659.001]
  • [Cites] Eur Urol. 2003 Dec;44(6):672-81 [14644119.001]
  • [Cites] Oncology. 2005;69(5):391-8 [16319510.001]
  • [Cites] Cancer. 2004 Apr 15;100(8):1639-45 [15073851.001]
  • [Cites] Ann Oncol. 2006 May;17 Suppl 5:v118-22 [16807438.001]
  • [Cites] J Clin Oncol. 1992 Jul;10(7):1066-73 [1607913.001]
  • [Cites] Eur Urol. 2000 Jan;37(1):85-9 [10671791.001]
  • [Cites] Cancer. 2006 Jan 15;106(2):297-303 [16342065.001]
  • [Cites] Anticancer Res. 2006 Sep-Oct;26(5B):3865-9 [17094415.001]
  • [Cites] J Clin Oncol. 2000 May;18(9):1921-7 [10784633.001]
  • [Cites] J Clin Oncol. 1990 Jun;8(6):1050-5 [2189954.001]
  • [Cites] Cancer. 2005 Mar 15;103(6):1172-8 [15700264.001]
  • [Cites] BJU Int. 2005 Mar;95(4):497-502 [15705067.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2876-81 [10561365.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):220-8 [14665607.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3068-77 [11001674.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4602-8 [16034041.001]
  • [Cites] BJU Int. 2004 Jan;93(2):216-20 [14690486.001]
  • (PMID = 18988001.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


6. Smith Y, Hadway P, Ahmed S, Perry MJ, Corbishley CM, Watkin NA: Penile-preserving surgery for male distal urethral carcinoma. BJU Int; 2007 Jul;100(1):82-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Penile-preserving surgery for male distal urethral carcinoma.
  • OBJECTIVE: To evaluate medium-term outcome data from patients with distal urethral cancers treated with penile-preserving surgery.
  • PATIENTS AND METHODS: We analysed prospectively 18 consecutive men referred for the management of urethral carcinoma.
  • Tumours were staged according to the Tumour-Node-Metastasis classification and the patients offered penile-preserving surgery when tumours were limited to the glanular or penile urethra.
  • RESULTS: All 18 patients were suitable for penile-preserving surgery; the procedures were: three hypospadias formation with or without topical chemotherapy; four buccal mucosa urethroplasty; three glansectomy and reconstruction; six glansectomy, distal corporectomy, reconstruction and hypospadias formation; two urethrectomy with or with no excision of adjacent tunica albuginea.
  • CONCLUSION: Medium-term data show that penile-preserving surgery is a feasible treatment for men with distal urethral carcinoma, providing excellent local control without prejudicing survival; a longer follow-up is needed.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Penis / surgery. Urethral Neoplasms / surgery. Urologic Surgical Procedures, Male / standards
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Feasibility Studies. Follow-Up Studies. Humans. Male. Middle Aged. Prospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488307.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


7. Matsumoto S, Nishioka T, Akiyama T, Park YC, Kurita T, Ishikawa Y: [A case of squamous cell carcinoma of the bladder that was successfully treated with multidisciplinary therapies]. Hinyokika Kiyo; 2001 Jan;47(1):43-6
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of squamous cell carcinoma of the bladder that was successfully treated with multidisciplinary therapies].
  • Endoscopic examination revealed a disintegration abscess between the bladder neck and prostatic urethra.
  • Transurethral biopsy demonstrated squamous cell carcinoma of the bladder.
  • He received 40 Gy of radiation combined with M-VAC (methotrexate, vinblastine, dovorubicin cisplatin) chemotherapy.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cystectomy. Doxorubicin / administration & dosage. Humans. Male. Methotrexate / administration & dosage. Middle Aged. Radiotherapy, Adjuvant. Treatment Outcome. Urethra / surgery. Vinblastine / administration & dosage

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11235221.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate; M-VAC protocol
  •  go-up   go-down


8. Tsukamoto T, Yonese J, Kin T, Samejima T, Hasegawa Y, Fukui I, Ishikawa Y: [Carcinoma in situ of the penis rapidly progressing after carbon dioxide laser treatment]. Nihon Hinyokika Gakkai Zasshi; 2002 Mar;93(3):483-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Carcinoma in situ of the penis rapidly progressing after carbon dioxide laser treatment].
  • Laser treatment is considered to be effective in treating carcinoma in situ of the penis.
  • We, however, report a case with carcinoma in situ of the penis which developed invasive carcinoma and inguinal lymphnode metastases only 6 months after the laser treatment.
  • A physical examination revealed thick erythema, 12 millimeters in diameter, around the external urethral meatus.
  • Histologically, biopsy revealed squamous cell carcinoma in situ.
  • Although the lesion appeared to slightly extend into the urethra, it was primarily treated with the CO2 laser.
  • Six months after the treatment, however, local recurrence was confirmed by the touch smear cytology, resulting in the partial amputation of the penis.
  • The histopathological examination revealed subepithelial and marked lymphatic invasion of the tumor and positive margin in the urethral stump (squamous cell carcinoma in situ).
  • The patient received adjuvant chemotherapy and has been alive and well without evidence of disease 40 months after the initial treatment.
  • [MeSH-major] Carcinoma in Situ / pathology. Lasers / adverse effects. Penile Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11968805.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


9. Tazi K, Moudouni S, Karmouni T, Koutani A, Hachimi M, Lakrissa A: [Epidermoid carcinoma of the male urethra]. Prog Urol; 2000 Sep;10(4):600-2
Genetic Alliance. consumer health - Epidermoid Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epidermoid carcinoma of the male urethra].
  • Squamous cell carcinoma of the male urethra is exceptional, as all urethral tumours represent less than 1% of urinary tract tumours.
  • Treatment depends on the stage and site of the lesion, but the prognosis remains very poor despite aggressive treatment, including mutilating resection surgery with or without associated radiotherapy.
  • However, the current hope for patients with squamous cell carcinoma of the urethra resides in radiotherapy-chemotherapy combination protocols based on the results obtained in squamous cell cancers of the oesophagus and anus.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Urethral Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11064906.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] FRANCE
  • [Number-of-references] 15
  •  go-up   go-down


10. Nicholson S, Tsang D, Summerton D: Aggressive combined-modality therapy for squamous cell carcinoma of the female urethra. Nat Clin Pract Urol; 2008 Oct;5(10):574-7
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive combined-modality therapy for squamous cell carcinoma of the female urethra.
  • INVESTIGATIONS: Pelvic examination under anesthetic by both a urologist and gynecologist, biopsy of the urethral tumor and of the cervix, pathological analysis, MRI of the pelvis, CT of the chest, abdomen and pelvis.
  • DIAGNOSIS: Poorly differentiated squamous cell carcinoma of the urethra, T4N0M0.
  • MANAGEMENT: The patient received two cycles of neoadjuvant TIP (paclitaxel, ifosfamide, cisplatin) chemotherapy, resulting in complete remission, followed by consolidative chemoradiation therapy (radiation therapy given with synchronous weekly cisplatin).
  • She remained relapse-free 48 months after diagnosis, with normal voiding and sexual function.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Urethral Neoplasms / drug therapy. Urethral Neoplasms / radiotherapy
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18762780.001).
  • [ISSN] 1743-4289
  • [Journal-full-title] Nature clinical practice. Urology
  • [ISO-abbreviation] Nat Clin Pract Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Hettiarachchi JA, Johnson GB, Panageas E, Drinis S, Konno S, Das AK: Malignant priapism associated with metastatic urethral carcinoma. Urol Int; 2001;66(2):114-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant priapism associated with metastatic urethral carcinoma.
  • We present a 40-year-old man with malignant priapism secondary to urethral squamous cell carcinoma.
  • Magnetic resonance imaging revealed the tumor originating from the bulbous urethra, extending into the penile urethra and corpora spongiosa and cavernosa.
  • A penile biopsy confirmed poorly differentiated squamous cell carcinoma of the urethra.
  • Despite administration of systemic chemotherapy, the prognosis of the patient has worsened due to the extensive metastatic disease.
  • [MeSH-major] Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / secondary. Priapism / etiology. Urethral Neoplasms / complications. Urethral Neoplasms / secondary

  • Genetic Alliance. consumer health - Priapism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 S. Karger AG, Basel
  • (PMID = 11223757.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


12. Hakenberg OW, Franke HJ, Froehner M, Wirth MP: The treatment of primary urethral carcinoma--the dilemmas of a rare condition: experience with partial urethrectomy and adjuvant chemotherapy. Onkologie; 2001 Feb;24(1):48-52
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The treatment of primary urethral carcinoma--the dilemmas of a rare condition: experience with partial urethrectomy and adjuvant chemotherapy.
  • BACKGROUND: Primary urethral carcinoma is a very rare condition, and no large-scale experience with such cases has been published.
  • Treatment will therefore have to follow rules established for the treatment of similar conditions.
  • PATIENTS: Six cases of primary urethral carcinoma (5 male, 1 female) who had been treated at our institution between 1995 and 1999 were retrospectively analyzed.
  • In 3 male cases, a primary urothelial carcinoma of the distal urethra was treated by distal urethrectomy only.
  • In 3 other cases with locally advanced tumors and/or lymph node metastases surgical treatment was followed by adjuvant cisplatinum-containing chemotherapy.
  • RESULTS: In the 3 cases with distal urethral carcinoma, partial urethrectomy with preservation of the penis resulted in cure, with a follow-up of 12-71 months.
  • In the cases with advanced disease, adjuvant chemotherapy after surgery has resulted in complete remissions in all 3 cases, with a follow-up of 4-47 months at present.
  • CONCLUSIONS: In localized, noninvasive carcinoma of the distal male urethra, partial urethrectomy seems adequate and the avoidance of penile amputation justified.
  • In advanced cases, after local excision and lymphadenectomy adjuvant chemotherapy which by necessity must follow the guidelines established for the treatment of other urothelial or squamous cell malignancies seems to be beneficial.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Carcinoma, Transitional Cell / surgery. Urethral Neoplasms / surgery
  • [MeSH-minor] Adult. Biopsy. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Urethra / pathology. Urethra / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 S. Karger GmbH, Freiburg
  • (PMID = 11441281.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  •  go-up   go-down


13. Osai WE, Ng CS, Pagliaro LC: Positive response to bevacizumab in a patient with metastatic, chemotherapy-refractory urothelial carcinoma. Anticancer Drugs; 2008 Apr;19(4):427-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positive response to bevacizumab in a patient with metastatic, chemotherapy-refractory urothelial carcinoma.
  • We report the case of a 78-year-old man with metastatic transitional-cell carcinoma with squamous differentiation that responded dramatically to the monoclonal antibody agent, bevacizumab.
  • The tumor originated in the bulbar urethra, with histology of poorly differentiated urothelial carcinoma.
  • Metastasis to a right inguinal lymph node was biopsy-confirmed as transitional-cell carcinoma with areas of keratinization.
  • At last follow-up, he had received 24 months of bevacizumab treatment with minimal toxicity and a positive response.
  • Mediators of angiogenesis have been implicated in the clinical progression of bladder cancer, although the role of angiogenesis inhibitors as treatment has not yet been defined.
  • The striking benefit achieved in this heavily treated patient suggests that bevacizumab could have clinically useful antitumor activity in advanced urothelial carcinoma.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Drug Resistance, Neoplasm. Urethral Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18454053.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


14. Serretta V, Pomara G, Piazza F, Gange E: Pure squamous cell carcinoma of the bladder in western countries. Report on 19 consecutive cases. Eur Urol; 2000 Jan;37(1):85-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pure squamous cell carcinoma of the bladder in western countries. Report on 19 consecutive cases.
  • INTRODUCTION: Pure squamous carcinoma (SCC) is a rare entity in western regions.
  • The management of SCC still remains similar to that of transitional carcinoma, although it is a different entity.
  • Involvement of prostatic urethra and upper urinary tract was evident in 9 (47.3%) and 5 patients (26.3%), respectively.
  • Four patients were submitted to neoadjuvant chemotherapy and 1 to presurgical radiotherapy without any objective response.
  • Adjuvant chemotherapy was performed in 3 patients.
  • CONCLUSIONS: Invasion of the upper urinary tract and prostatic urethra seems more common in SCC than in transitional cell carcinoma.
  • Preoperative radiotherapy should be considered since pelvic recurrences are the leading cause of progression in squamous cell carcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell. Urinary Bladder Neoplasms

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10671791.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] SWITZERLAND
  •  go-up   go-down


15. Rinaldi M, Cormio G, Bucaria V, Di Tonno P, Marino F, Altomare DF: [Reconstruction with skin flaps of the posterior aspect of the thighs after total pelvic evisceration with removal of vulvo-perineal soft tissues in recurrent vulvar squamous carcinoma]. Suppl Tumori; 2005 May-Jun;4(3):S208
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Reconstruction with skin flaps of the posterior aspect of the thighs after total pelvic evisceration with removal of vulvo-perineal soft tissues in recurrent vulvar squamous carcinoma].
  • [Transliterated title] Ricostruzione con lembi cutanei della faccia posteriore delle cosce dopo evisceratio pelvica totale con asportazione dei tessuti molli vulvo-perineali per carcinoma squamoso vulvare recidivo.
  • We report of a case of a fortythree years old women affected by squamous cell cancer of the vulva (T3N0M0).
  • Despite curative treatment (radical vulvectomy with bilateral inguinal and femoral lymphadenectomy), after 41 months she had a local recurrence, retreated with surgery and radiotherapy; another recurrence, after 29 months was treated with chemotherapy, without results.
  • Because of local diffusion with infiltration of the urethra and anus, the patient was submitted to demolitive operation (total pelvic evisceratio, excision of pelvic and perineal soft tissues and reconstruction with rotating skin flaps of the posterior face of the thighs).
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Neoplasm Recurrence, Local / surgery. Pelvic Exenteration. Perineum. Reconstructive Surgical Procedures / methods. Soft Tissue Neoplasms / surgery. Surgical Flaps. Thigh / surgery. Vulvar Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437992.001).
  • [ISSN] 2283-5423
  • [Journal-full-title] I supplementi di Tumori : official journal of Società italiana di cancerologia ... [et al.]
  • [ISO-abbreviation] Suppl Tumori
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


16. Tamura N, Aoki Y, Fujita K, Tanaka K: Stage IVa squamous cell carcinoma of the vulva managed with primary chemoradiation. Int J Clin Oncol; 2005 Apr;10(2):148-51
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage IVa squamous cell carcinoma of the vulva managed with primary chemoradiation.
  • We present the case of a 53-year-old woman with International Federation of Gynecology and Obstetrics stage IVa (T3N2M0) squamous cell carcinoma of the vulva.
  • Because the urethra was surrounded by a vulvar tumor, she was managed with primary chemoradiation in an attempt to spare the morbidity associated with exenterative vulvar surgery.
  • Treatment was given as a planned split course, consisting of two separate courses of 23.8 Gy each.
  • During the 4 days of chemotherapy infusion, the radiation was administered in two daily fractions of 1.7 Gy each, given at least 6 h apart.
  • There was no treatment break due to adverse effect, and a pathological complete response was achieved in the primary tumor and the lymph nodes.
  • Chemoradiation therapy should be considered as an option in patients with locally advanced vulvar cancer to avert the need for exenterative surgery, and to preserve sexual, gastrointestinal, and urinary function.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Fluorouracil / therapeutic use. Vulvar Neoplasms / drug therapy. Vulvar Neoplasms / radiotherapy
  • [MeSH-minor] Combined Modality Therapy. Disease-Free Survival. Female. Humans. Infusions, Intravenous. Middle Aged. Treatment Outcome. Urethra / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15864703.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


17. Bissada NK, Yakout HH, Fahmy WE, Gayed MS, Touijer AK, Greene GF, Hanash KA: Multi-institutional long-term experience with conservative surgery for invasive penile carcinoma. J Urol; 2003 Feb;169(2):500-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multi-institutional long-term experience with conservative surgery for invasive penile carcinoma.
  • PURPOSE: Invasive squamous cell carcinoma of the penis occurs on the glans, prepuce, glans and prepuce, coronal sulcus and shaft.
  • Penile squamous cell carcinoma subsequently invades local structures, corpora cavernosa and the urethra, and metastasizes to the inguinal lymph nodes.
  • Invasive squamous cell carcinoma of the penis usually requires total or partial penectomy.
  • We studied the effect of primary tumor resections tailored to the anatomical extent of the cancer with preservation of uninvolved structures in select patients with invasive penile squamous cell carcinoma.
  • Chemotherapy was given to 7 patients with extensive inguinal lymphadenopathy and to 2 of 5 with pathologically positive lymph nodes.
  • Tumor resection with no sacrifice of function was performed in 2 patients in whom 3 small recurrences developed.
  • The anatomical situation and tumor characteristics should dictate the choice of treatment for the primary penile lesion.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Humans. Male. Middle Aged. Neoplasm Invasiveness. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12544296.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


18. Salom EM, Penalver M: Recurrent vulvar cancer. Curr Treat Options Oncol; 2002 Apr;3(2):143-53
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recurrent vulvar cancer occurs in an average of 24% of cases after primary treatment after surgery with or without radiation.
  • The relatively few primary vulvar cancers, combined with the low proportion of recurrences, has made it difficult to perform randomized studies to document the most appropriate therapeutic modalities.
  • Traditionally, the most accepted treatment of vulvar cancer has been and continues to be surgery.
  • Recently, radiation and chemotherapy have been combined with very encouraging results.
  • The therapeutic modality used depends on the location and extent of the recurrence.
  • With a central pelvic recurrence with antecedent radiotherapy involving the urethra, upper vagina, and rectum, total pelvic exenteration is indicated in a select group of patients with curative intent.
  • We recommend that inguinal recurrences without prior radiation therapy undergo excision followed by radiotherapy with chemosensitization.
  • With pelvic recurrences, we recommended chemoradiation as the treatment modality.
  • In the subset of patients with distant metastasis, chemotherapy may be offered; however, few studies have been performed to advocate any single combination.
  • The literature supports the use of 5-fluorouracil or cisplatin as single agents or in combination to have sensitivity against squamous cells.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Neoplasm Recurrence, Local / therapy. Vulvar Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Practice Guidelines as Topic

  • Genetic Alliance. consumer health - Vulvar cancer.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Obstet Gynecol. 1990 Sep;163(3):1007-15 [2403127.001]
  • [Cites] Cancer. 1984 Nov 1;54(9):1943-9 [6478428.001]
  • [Cites] Am J Obstet Gynecol. 1999 Jul;181(1):91-8 [10411801.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 15;46(5):1193-7 [10725631.001]
  • [Cites] Am J Obstet Gynecol. 1990 May;162(5):1278-82 [2339729.001]
  • [Cites] Gynecol Oncol. 1995 Aug;58(2):202-5 [7622106.001]
  • [Cites] Gynecol Oncol. 1989 Sep;34(3):263-7 [2504651.001]
  • [Cites] Acta Radiol Oncol. 1984;23(5):345-8 [6095605.001]
  • [Cites] Am J Obstet Gynecol. 1992 Nov;167(5):1383-9 [1442996.001]
  • [Cites] Gynecol Oncol. 1993 Feb;48(2):189-95 [8428690.001]
  • [Cites] Eur J Gynaecol Oncol. 1993;14(4):318-22 [8344328.001]
  • [Cites] Am J Obstet Gynecol. 1998 Aug;179(2):343-8 [9731836.001]
  • [Cites] Obstet Gynecol. 1990 Jun;75(6):1001-5 [2342725.001]
  • [Cites] Cancer. 1992 Dec 15;70(12):2835-8 [1451064.001]
  • [Cites] Cancer. 1984 Nov 15;54(10):2062-8 [6435851.001]
  • [Cites] Gynecol Oncol. 1986 Feb;23(2):192-8 [3943761.001]
  • [Cites] Gynecol Oncol. 1996 Jun;61(3):321-7 [8641609.001]
  • [Cites] Gynecol Oncol. 1995 Oct;59(1):51-6 [7557615.001]
  • [Cites] Gynecol Oncol. 1990 Sep;38(3):309-14 [2227541.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1987 Mar;13(3):403-26 [3549645.001]
  • [Cites] Am J Obstet Gynecol. 1982 Jun 1;143(3):340-51 [7081350.001]
  • [Cites] Gynecol Oncol. 1991 Sep;42(3):197-201 [1955180.001]
  • [Cites] Am J Clin Oncol. 1987 Apr;10(2):171-81 [3565317.001]
  • [Cites] Gynecol Oncol. 1992 Oct;47(1):14-20 [1427394.001]
  • (PMID = 12057077.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Number-of-references] 27
  •  go-up   go-down


19. Coulter J, Gleeson N: Local and regional recurrence of vulval cancer: management dilemmas. Best Pract Res Clin Obstet Gynaecol; 2003 Aug;17(4):663-81
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Approximately one-third of patients develop recurrent disease usually within the first 2 years following primary treatment.
  • Radical exenterative procedures are considered when the recurrence involves the urethra, bladder, vagina and/or the anorectal canal.
  • Chemoradiation therapy may be used pre-operatively or to palliate the disease.
  • Surgical effort to debulk large-volume groin disease is often unsuccessful and chemoradiation therapy is the cornerstone of treatment.
  • The management of retroperitoneal and distant disease recurrence is generally based on symptom control as radiation therapy and chemotherapy have limited success.
  • Palliative medicine should be integrated early in the management plan both in patients with incurable recurrent disease and in those undergoing potentially curative treatments.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Neoplasm Recurrence, Local / therapy. Palliative Care / methods. Vulvar Neoplasms / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Female. Hemorrhage / therapy. Humans. Inguinal Canal. Neoadjuvant Therapy. Pelvis. Radiotherapy, Adjuvant. Terminal Care / methods

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12965138.001).
  • [ISSN] 1521-6934
  • [Journal-full-title] Best practice & research. Clinical obstetrics & gynaecology
  • [ISO-abbreviation] Best Pract Res Clin Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 55
  •  go-up   go-down


20. Das S, Tunuguntla HS: Balanitis xerotica obliterans--a review. World J Urol; 2000 Dec;18(6):382-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Many cases of BXO occurring after circumcision may be cases of secondary phimosis due to BXO not being recognized at the time of surgery.
  • Early diagnosis and treatment of BXO are very important in preventing the urological complications of the diseases such as urethral stricture.
  • Treatment of BXO depends on the anatomic location of the lesions and their extent and severity, together with the rapidity of progression of the disease process.
  • The treatment may vary from topical corticosteroids, laser vaporization in early cases to meatoplasty and urethroplasty in extensive cases.
  • Topical pharmacotherapy is useful in the early stages to reduce the initial symptoms and slow down the progression, but is not effective in all cases and is not the curative treatment of disease.
  • Meatal stenosis, phimosis, scar adhesions, fissures, erosions of glans and prepuce and involvement of the urethra are indications for surgical treatment.
  • Surgery seems to be the only treatment that can relieve the symptoms of advanced disease.
  • BXO involving anterior urethra can be treated by 2-stage urethroplasty or substitution urethroplasty.
  • The complete excision of the stricture and flap urethroplasty seems to be better than a 2-stage procedure.
  • However, at the present time, it is not possible to say that surgery can completely resolve this chronic and progressive disease.
  • Despite many reports in the literature of cases of BXO associated with squamous cell carcinoma, the etiologic relationship between the two conditions is uncertain.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11204255.001).
  • [ISSN] 0724-4983
  • [Journal-full-title] World journal of urology
  • [ISO-abbreviation] World J Urol
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  • [Number-of-references] 27
  •  go-up   go-down


21. Rogers LJ, Howard B, Van Wijk L, Wei W, Dehaeck K, Soeters R, Denny LA: Chemoradiation in advanced vulval carcinoma. Int J Gynecol Cancer; 2009 May;19(4):745-51
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoradiation in advanced vulval carcinoma.
  • INTRODUCTION: Vulval carcinoma is uncommon, affecting approximately 2 per 100,000 women annually.
  • The treatment of choice is radical vulvectomy and inguinal lymph node dissection.
  • Advanced vulval carcinomas involve midline structures (such as clitoris, urethra, or anus) and/or adjacent pelvic organs or bone, and adequate excision may require urinary diversion, colostomy, or pelvic exenteration.
  • Less morbid and less mutilating therapeutic alternatives have been investigated, particularly chemoradiation, which has shown success in the management of anal carcinomas.
  • This is a retrospective study of the GSH's experience of the use of chemoradiation as primary therapy for women with advanced vulval carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Vulvar Neoplasms / drug therapy. Vulvar Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Middle Aged. Mitomycin / administration & dosage. Neoplasm Staging. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19509582.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


22. Lee DJ, Rothberg MB, McKiernan JM, Benson MC, Badani KK: Robot-assisted radical cystoprostatectomy in complex surgical patients: single institution report. Can J Urol; 2009 Jun;16(3):4664-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the safety and feasibility of robotic-assisted radical cystoprostatectomy (RRCP) in a salvage setting for patients with a history of radiation and chemotherapy treatment, complex pelvic anatomy, and significant comorbidities.
  • MATERIALS AND METHODS: Over a 5 month period, six patients who met these criteria underwent RRCP for urothelial carcinoma.
  • Two of the patients had major cardiovascular disease and were previously denied an open procedure subsequently underwent chemotherapy with external beam radiation protocol.
  • One patient had brachytherapy for prior prostate cancer, and three additional patients had neoadjuvant chemotherapy with large diverticula, measuring up to 12 cm in size.
  • Four patients had pathologic pT3a disease, one patient had pT4a, and one patient had pT1 urethral squamous cell carcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Carcinoma, Transitional Cell / surgery. Cystectomy / methods. Prostatectomy / methods. Robotics. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Humans. Male. Middle Aged. Salvage Therapy. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Can J Urol. 2009 Jun;16(3):4670 [19497176.001]
  • (PMID = 19497175.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


23. Gómez Díaz ME, Castaño González-Coto D, Cuervo Calvo J, Muruamendiaraz Fernández V: [Cancer of the female urethra. Report of a new case a review of the literature]. Arch Esp Urol; 2002 Jun;55(5):568-71

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cancer of the female urethra. Report of a new case a review of the literature].
  • OBJECTIVE: To review the main features of female urethral cancer, the only genitourinary neoplasm with a predilection for women, the ratio being 4:1.
  • Female urethral cancer is an uncommon neoplasm that accounts for only 0.02% of all cancers found in women.
  • METHODS: A case of female urethral cancer in a 52-year-old woman is presented.
  • RESULTS/CONCLUSIONS: Female urethral cancer is an uncommon neoplasm.
  • For patients with Ta-2N0M0 tumors, multimodality therapy may not be required.
  • For patients with T3-4N0M0 tumors, the best results are obtained with multimodal radiation and chemotherapy with surgical resection.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Urethral Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12174428.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 9
  •  go-up   go-down


24. Tamas EF, Nielsen ME, Schoenberg MP, Epstein JI: Lymphoepithelioma-like carcinoma of the urinary tract: a clinicopathological study of 30 pure and mixed cases. Mod Pathol; 2007 Aug;20(8):828-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoepithelioma-like carcinoma of the urinary tract: a clinicopathological study of 30 pure and mixed cases.
  • We studied 28 cases of lymphoepithelioma-like carcinoma of the bladder, one case in the renal pelvis, and one in the urethra.
  • Seventeen cases (56.7%) were pure with the remaining mixed with other patterns of carcinoma, including invasive urothelial carcinoma (n=10), invasive adenocarcinoma (n=3), and squamous cell carcinoma (n=2).
  • The surface demonstrated carcinoma in situ (CIS) in six cases, noninvasive high-grade papillary urothelial carcinoma in three cases, and in situ adenocarcinoma in one case.
  • Treatment consisted of radical cystectomy in 13/30 cases (43%); partial cystectomy in 4/30 cases (13%); nephrectomy in one case (3%), and transurethral resection often followed by radiation or chemotherapy in 12/30 (40%) cases.
  • Lymphoepithelioma-like carcinoma, whether in pure or mixed form, has a similar prognosis to ordinary urothelial carcinoma when treated by cystectomy.
  • Of the three pure cases treated by chemotherapy, two were free of disease at 4 and 65 months and the third had recurrent disease at 17 months.
  • Given the association of lymphoepithelioma-like carcinoma with urothelial carcinoma in 47% of our cases and its propensity for multifocality, partial cystectomy would typically be ill advised for lymphoepithelioma-like carcinoma.
  • [MeSH-major] Carcinoma / pathology. Urologic Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Aged. Aged, 80 and over. Carcinoma in Situ / pathology. Carcinoma, Squamous Cell / pathology. Cell Differentiation. Disease-Free Survival. Epithelial Cells / pathology. Female. Follow-Up Studies. Humans. Lymphocytes / pathology. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17541442.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Gadducci A, Cionini L, Romanini A, Fanucchi A, Genazzani AR: Old and new perspectives in the management of high-risk, locally advanced or recurrent, and metastatic vulvar cancer. Crit Rev Oncol Hematol; 2006 Dec;60(3):227-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During the last decades there has been a continuing evolution in the surgical approach of squamous cell carcinoma of the vulva that has been traditionally treated with radical vulvectomy and bilateral inguinal-femoral lymphadenectomy.
  • Modifications of the surgical technique of deep femoral lymphadenectomy and the mapping of sentinel node can offer new interesting therapeutic perspectives.
  • Locally advanced squamous cell carcinoma of the vulva has been long surgically treated with en-block radical vulvectomy and bilateral inguinal-femoral lymphadenectomy plus partial resection of urethra, vagina or anum, or by exenteration, with severe postsurgical complications, poor quality of life, and unsatisfactory survival rates.
  • 5-Fluorouracil [5-FU] or 5-FU- and cisplatin-based chemotherapy concurrent with irradiation followed by tailored surgery represents an attractive therapeutic option for advanced disease, planned to avoid such ultra-radical surgical procedures and, hopefully, to improve patient outcome.
  • Chemotherapy has also been used in neoadjuvant setting, with contrasting and generally unsatisfactory results, and in palliative treatment of patients with distant metastases.
  • Surgery is the primary treatment also for vulvar malignancies other than squamous cell carcinoma, whereas the clinical usefulness of adjuvant irradiation or chemotherapy is still to be defined.
  • Primary chemoradiation can be also used for advanced carcinoma of the Bartholin gland or for advanced adenocarcinoma associated with extramammary Paget's disease.
  • The drugs used for chemotherapy of metastatic melanomas or sarcomas of the vulva are the same employed for the melanomas or sarcomas developed in other sites.
  • [MeSH-major] Vulvar Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Neoplasm Metastasis. Recurrence

  • Genetic Alliance. consumer health - Vulvar cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16945551.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 167
  •  go-up   go-down


26. Yoshioka Y, Nishimura T, Kamata M, Harada H, Kanazawa K, Fuji H, Murayama S, Hirashima Y, Yamada Y: [High-dose-rate interstitial brachytherapy using inverse planning for locally advanced cervical cancer]. Nihon Igaku Hoshasen Gakkai Zasshi; 2003 Mar;63(4):171-6
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 56-year-old woman with bulky cervical cancer was treated with high-dose-rate interstitial brachytherapy combined with external beam irradiation and chemotherapy.
  • Inverse planning (IP) was used in the treatment planning for brachytherapy.
  • As for sparing OARs such as the bladder, urethra, and rectum, IP showed the best % V75.
  • The calculation time of the computer was fast enough.
  • [MeSH-major] Brachytherapy / methods. Carcinoma, Squamous Cell / radiotherapy. Radiotherapy Planning, Computer-Assisted / methods. Uterine Cervical Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Cervical cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12708060.001).
  • [ISSN] 0048-0428
  • [Journal-full-title] Nihon Igaku Hōshasen Gakkai zasshi. Nippon acta radiologica
  • [ISO-abbreviation] Nihon Igaku Hoshasen Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


27. Nakano M, Iwasaki M, Yoshimura Y, Yamaguchi O, Uchida H, Hashimoto T: [A case of long-term survival of advanced penile carcinoma treated with combination therapy]. Nihon Hinyokika Gakkai Zasshi; 2007 Sep;98(6):776-80
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of long-term survival of advanced penile carcinoma treated with combination therapy].
  • The pathological examination revealed well differentiated squamous cell carcinoma.
  • A diagnosis by computed tomography and magnetic resonance imaging indicated that a locally advanced penile carcinoma had infiltrated the urethra, prostate, pubic bone and there was also bilateral inguinal lymphoadenopathy.
  • One month after the combination therapy, the tumor size had become small enough to allow curative surgical treatment.
  • For eight years since this radical treatment, the patient has been healthy with no local recurrence and no distant metastatic lesion.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Penile Neoplasms / therapy
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Combined Modality Therapy. Doxorubicin / administration & dosage. Doxorubicin / analogs & derivatives. Drug Administration Schedule. Humans. Lymph Node Excision. Male. Survivors

  • Hazardous Substances Data Bank. BLEOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17929460.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 80168379AG / Doxorubicin; D58G680W0G / pirarubicin
  •  go-up   go-down


28. Lee KC: Carcinoma of the female urethra responsive to moderate dose chemoradiotherapy. J Urol; 2000 Mar;163(3):905-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma of the female urethra responsive to moderate dose chemoradiotherapy.
  • [MeSH-major] Carcinoma, Squamous Cell / chemistry. Carcinoma, Squamous Cell / radiotherapy. Urethral Neoplasms / drug therapy. Urethral Neoplasms / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10688008.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down






Advertisement